Moderator: Joshua Sisco

September 9, 2022

Josh Sisco is a reporter with POLITICO, where he covers antitrust enforcement, policy and litigation. His coverage is focused on how regulators and policy makers are fighting to rein in corporate power and the pushback from the companies and their Washington allies.

Josh has spent the last nine years on the antitrust beat, most recently at The Information, where he covered the heightened scrutiny of the tech giants, including Google, Apple, Meta, Amazon and Microsoft. Josh is an experienced legal and financial journalist who follows civil and criminal antitrust litigation along with government investigations. He has previously worked for publications including MLex, the Policy and Regulatory Report and The Capitol Forum.

Josh earned his B.A. in communications at Sonoma State University in Northern California, studying journalism and sociology.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor